OctreoPharm Sciences GMBH
Radiolabeled diagnostics and treatments for neuroendocrine tumors
This article was originally published in Start Up
Executive Summary
The founders of OctreoPharm Sciences GMBH aim to commercialize new kinds of radiolabeled pharmaceuticals to treat all kinds of neuroendocrine tumors, plus matching diagnostics to improve physicians’ ability to detect and monitor these rare cancers. Beyond exclusive rights to relevant intellectual property, the founders’ backgrounds suggest they possess skills appropriate to the task